SYNGR3 and HIV infectious disease: Additionally, using an AI-assisted molecular docking approach, we determined that ritonavir, an FDA-approved drug for HIV infection, like blocking peptide P-2A, can effectively disrupt the binding of Syn2a with Syngr3 and enhance fear extinction in mice.